Caption Management’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.48M Buy
159,500
+9,500
+6% +$328K 0.03% 517
2026
Q1
$4.72M Buy
150,000
+72,500
+94% +$2.09M 0.03% 550
2025
Q4
$1.92M Buy
+77,500
New +$1.56M 0.01% 849
2025
Q2
Sell
-650,300
Closed -$14.3M 1596
2025
Q1
$14.3M Buy
650,300
+352,100
+118% +$9.24M 0.14% 134
2024
Q4
$7.96M Sell
298,200
-522,000
-64% -$16.6M 0.08% 244
2024
Q3
$21.9M Buy
+820,200
New +$16.3M 0.35% 60

Other funds holding EWTX

Caption Management's EWTX Position: Q2 2026 in Review

Caption Management sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 38,675 shares — an estimated $1.33M sold.

Caption Management first reported a position in EWTX in Q1 2025 and held it in 2 quarters. The position peaked at $4.5M in Q1 2025. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Caption Management reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 38,675 Edgewise Therapeutics shares in Q2 2026, an estimated $1.33M.
  • Caption Management first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 2 quarters.
  • Caption Management's Edgewise Therapeutics position peaked at $4.5M in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.